An interventional study of Carbon dioxide Laser ablation and Electrocoagulation in Condylomata Acuminata, sponsored by Ruhr University of Bochum. Completed at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Ruhr University of Bochum · Not applicable, Interventional, and Treatment
In a randomized clinical trial of 114 women undergoing Treatment for condyloma acuminata, two surgical methods, the carbon dioxide laser Ablation and the excision by electrocoagulation, will be compared. The primary outcome of the study is the cosmetic result judged by the Patient 6 weeks after Treatment using a 11-step numerical rating scale (NRS), secondary outcomes are intervention time, operative complications, subjects and users satisfaction, postoperative pain and recurrence of genital warts.
116 studies on the registry are indexed under Condylomata Acuminata; 11 are open to participants now.
This study's enrollment of 140 is below the median of 158 across 95 interventional studies indexed under Condylomata Acuminata.
Browse Condylomata Acuminata studies →Ruhr University of Bochum is the lead sponsor of 126 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excision of genital warts using a carbon dioxide laser, ie CO2 Laser
Device: Carbon dioxide Laser ablation
Excision of genital warts using a superficial electrical coagulation mode, ie spray coagulation
Device: Electrocoagulation
surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage - NOTE: pulsed 15 W was never used; the actual setting was 5W continuous
surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
Cosmetic result
Cosmetic result judged by the Patient 6 weeks after Treatment using a 11-step numerical rating scale (NRS)
Time frame: 6 weeks
users satisfaction
surgeons will score their satisfaction concerning the used technique by using a 11-step numerical rating scale (NRS) within 30 minutes after surgery
Time frame: 30 minutes
Operation time
the time from the beginning of the Treatment until the end of the operation (the end of hemostatic interventions) will be measured in minutes
Time frame: 20 minutes
Postoperative pain
patients will score their postoperative pain Level using a 11-step numerical rating scale (NRS) within 5 hours after surgery
Time frame: 5 hours
Subjects satisfaction
Patients will score their Overall satisfaction by using a 11-step numerical rating scale (NRS) 6 weeks after Treatment
Time frame: 6 weeks
Recurrence of genital warts
an examination will be performed 12 weeks after surgery; Recurrence of genital warts will be determined if one or more Areas are infected by genital warts
Time frame: 12 weeks
Operative complications
Operative complications defined as necessity to intervene surgically up to 14 days postoperatively (number of patients with operative complications and type of complication)
Time frame: 14 days
Subjects satisfaction
Patients will score their Overall satisfaction by using a 11-step numerical rating scale (NRS) 12 weeks after Treatment
Time frame: 12 weeks
Cosmetic result
Cosmetic result judged by the Patient 12 weeks after Treatment using a 11-step numerical rating scale (NRS)
Time frame: 12 weeks
Plan to share: Yes — The datasets generated and analyzed during the current study are not publicly available due to patient confidentiality and institutional data-protection policies, but they can be made available from the corresponding author on reasonable request. Requests will be evaluated to ensure that proposed use complies with ethical approvals and data-use agreements.
No publications or documents are linked to this record.
Ran from Oct 2016 to primary completion in Dec 2025, 109 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.